• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Wave Life Sciences Ltd. (Amendment)

    2/14/23 4:08:05 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $WVE alert in real time by email
    SC 13G/A 1 d400612dsc13ga.htm SC 13G/A SC 13G/A

     

     

    United States

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    WAVE LIFE SCIENCES LTD.

    (Name of Issuer)

    Ordinary Shares

    (Title of Class of Securities)

    Y95308105

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed “ for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. Y95308105

     

      1.    

      Names of Reporting Persons

     

      BB Biotech AG

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Switzerland

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    with:

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      4,494,458

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      4,494,458

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,494,458

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      ☐

    11.  

      Percent of Class Represented by amount in Row (9)

     

      5.2%

    12.  

      Type of Reporting Person (See Instructions)

     

      HC,CO

     

    2 of 7


    CUSIP No. Y95308105

     

      1.    

      Names of Reporting Persons

     

      Biotech Target N.V.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Curacao

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    with:

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      4,494,458

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      4,494,458

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,494,458

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      ☐

    11.  

      Percent of Class Represented by amount in Row (9)

     

      5.2%

    12.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    3 of 7


    Item 1

    1(a) Name of Issuer: Wave Life Sciences Ltd.

    1(b) Address of Issuer’s Principal Executive Offices:

            7 Straits View #12-00, Marina One East Tower, Singapore 018936

    Item 2

    2(a) Name of Person Filing: BB Biotech AG (“BB Biotech”) on behalf of its wholly-owned subsidiary, Biotech Target N.V. (“Biotech Target”)

    2(b) Address of Principal Business Office or, if none, Residence:

            BB Biotech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland

            Biotech Target N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curaçao

    2(c) Citizenship: BB Biotech AG: Switzerland

                                   Biotech Target N.V.: Curacao

    2(d) Title of Class of Securities $0 Par Value Ordinary Shares

    2(e) CUSIP Number Y95308105

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned: 4,494,458

    (b) Percent of class: 5.2%

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote 0

    (ii) Shared power to vote or to direct the vote 4,494,458

    (iii) Sole power to dispose or to direct the disposition of 0

    (iv) Shared power to dispose or to direct the disposition of 4,494,458

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    This statement is filed jointly by BB Biotech and Biotech Target. Biotech Target is a wholly-owned subsidiary of BB Biotech.

     

    4 of 7


    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    5 of 7


    SIGNATURES

    After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    BB Biotech AG

     

    Date: February 10, 2023     By:  

    /s/ Daniel Koller

          Signatory Authority
        Name:  

    Daniel Koller

        Title:   Signatory Authority
    Date: February 10, 2023     By:  

    /s/ Ivo Betschart

          Signatory Authority
        Name:  

    Ivo Betschart

        Title:   Signatory Authority
    Biotech Target N.V.      
    Date: February 10, 2023     By:  

    /s/ Jan Bootsma

          Signatory Authority
        Name:  

    Jan Bootsma

        Title:   Signatory Authority
    Date: February 10, 2023     By:  

    /s/ Nathalie M.A. Isidora-Kwidama

          Signatory Authority
        Name:  

    Hugo van Neutegem

        Title:   Signatory Authority

     

    6 of 7


    Exhibit Index

    Exhibit A: Agreement by and between BB Biotech AG and Biotech Target N.V. with respect to the filing of this disclosure statement.*

    Exhibit B: Power of Attorney

     

    *

    Previously filed as an exhibit to BB Biotech AG and Biotech Target N.V.’s Schedule 13G filed with the Securities and Exchange Commission on December 23, 2019.

     

    7 of 7

    Get the next $WVE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WVE

    DatePrice TargetRatingAnalyst
    6/11/2025$14.00Outperform
    Raymond James
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    4/8/2025$18.00Outperform
    Wedbush
    2/25/2025$26.00Buy
    Jefferies
    10/16/2024$22.00Outperform → Strong Buy
    Raymond James
    9/27/2024$10.00 → $13.00Overweight
    JP Morgan
    9/19/2024$11.00Buy
    B. Riley Securities
    9/9/2024$10.00Overweight
    JP Morgan
    More analyst ratings